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RVX-208 a novel and orally active small molecule is known to increase apoA-I production in vitro and in vivo. In the African Green monkey, RVX-208 
acts rapidly within 4 days to raise plasma levels of apoA-I, HDL, pre-beta HDL, large alpha HDL and ex vivo cholesterol efflux mediated by SR-B1, 
ABCA1, and ABCG1. These promising preclinical data prompted us to perform a phase 1a human clinical trial. Results showed RVX-208 to be safe, 
well tolerated and had dose-proportional plasma exposure. The efficacy of RVX-208 was explored in 18 subjects given 2-8 mg/kg/d of RVX-208 
orally for 7 days (d) vs 6 placebos. RVX-208 increased apoA-I, pre-beta HDL and ABCA1 mediated cholesterol efflux by 10, 42 and 10%, respectively 
(p<0.05) with a trend towards higher alpha-1 HDL (17%) and HDL-c (10%). These data enabled us to move to a phase 1b/2a trial comprised of 3 
arms receiving; a low (2 mg/kg/d), a weekly dose-escalation (3-6 mg/kg/d), or a high (6 mg/kg/d) dose of RVX-208 given to 18 active subjects 
and 6 placebos per group for 28d. Again, RVX-208 was safe and well tolerated. ApoA-I levels rose significantly in both the low- and high-dose arms 
to 5.1 and 8.2% within 8d, respectively, and at 28d, there was a further rise to 6.5 and 10.4%, respectively. Similarly, HDL-c levels in the low and 
high-dose subjects were higher by 6.2% and 9.2 % at 8d, respectively, and at 28d HDL rose further to 7.4 and 15.1%, respectively. Ability to increase 
apoA-I and HDL appeared to be more robust in subjects with low HDL (<40 mg/dL). In summary, RVX-208 is first in its class of small molecules that 
raises endogenous apoA-I production & thereby enhances the synthesis of HDL. The findings in the 1b/2a trial extend human safety data from 7d 
to 28d and the RVX-208 rise in apoA-I and HDL is both dose & time dependent. Both apoA-I and HDL were higher at 28d vs 8d suggesting a further 
rise in these parameters may occur beyond 28d of treatment. As seen in previous apoA-I infusion studies, a rise in apoA-I (6.5%) and HDL (7.4%) 
by production in subjects given 2 mg/kg/d of RVX-208 should be sufficient to regress atherosclerosis in man. Furthermore, the enhanced activity of 
RVX-208 in subjects with low HDL points to the potential usefulness of this compound in the population at high risk for CVD.
